Nexalin Technology Inc (NXL)

$1.15 +0.14 (13.86%)
Market Cap 17.35M
Revenue (ttm) 170,000.00
Net Income (ttm) -7.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,476.47%
Debt to Equity Ratio 0.00
Volume 226,000
Avg Vol 104,278
Day's Range N/A - N/A
Shares Out 17.18M
Stochastic %K 87%
Beta 3.70
Analysts Strong Sell
Price Target $5.00

Company Profile

Nexalin Technology, Inc. designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy. It also offers Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury,...

Industry: Medical Devices
Sector: Healthcare
Phone: 832-260-0222
Address:
1776 Yorktown, Suite 550, Houston, United States
NewYorkBull
NewYorkBull Jul. 16 at 7:09 PM
$NXL guys I'm a proud owner. This will change lives if you hold through next year. I promise you we'll have trial data and a lot more.
0 · Reply
Painman
Painman Jul. 9 at 6:45 PM
$NXL 💩💩💩
0 · Reply
Painman
Painman Jun. 26 at 5:16 PM
$NXL ..Total POS scam being run by Len Osser
0 · Reply
Chrissytina
Chrissytina Jun. 25 at 1:14 PM
$NXL Anybody else noticed that since they took all these commercials off CNBC that most of them have crashed 🤣 crooks!!! Not complaining, I flipped 4 different ones 2/3 times! I want the commercials/volume to come back!!! 🙏🏻
1 · Reply
Painman
Painman Jun. 17 at 2:30 PM
$NXL ..💩💩🤪
0 · Reply
Msnlrainey
Msnlrainey May. 31 at 11:03 PM
$NXL back on tv again with red chip
0 · Reply
Painman
Painman May. 20 at 7:15 PM
$NXL Total garbage..🐕💩POS.. You can’t do deep brain stimulation or treat Alzheimer’s with skin electrodes! Check it out just another Lenny scam.
0 · Reply
TheLearnerEarner
TheLearnerEarner May. 15 at 3:08 PM
$NXL ✅ Healthcare - Micro Cap - Oversold F-Score: 3/9 🏦 Analysts: 1x buy rating 👨‍🔬 Potential: Revenue is forecast to grow per year 💎 Highest Analysts Price Target: $5.00 (309% above Price) 🌟 Range (12m) $0.53 - $4.49 💰 NEWSDESK (last recent article) 📰 https://www.stocktitan.net/news/NXL/nexalin-technology-reconstitutes-scientific-advisory-board-with-ja58t2vt6l1v.html
0 · Reply
Mohammed_kas
Mohammed_kas May. 13 at 2:09 PM
$NXL The news is good and this is red😔
0 · Reply
Mohammed_kas
Mohammed_kas May. 13 at 1:12 PM
$NXL Nexalen Technology reconstitutes its scientific advisory board with leading experts to advance its Alzheimer's program amid encouraging data.
0 · Reply
Latest News on NXL
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

May 28, 2025, 10:00 AM EDT - 7 weeks ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

May 13, 2025, 8:30 AM EDT - 2 months ago

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

May 6, 2025, 2:40 PM EDT - 2 months ago

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

May 5, 2025, 8:20 AM EDT - 2 months ago

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

May 1, 2025, 10:30 AM EDT - 2 months ago

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Apr 24, 2025, 9:00 AM EDT - 3 months ago

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Apr 23, 2025, 9:15 AM EDT - 3 months ago

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Apr 21, 2025, 8:00 AM EDT - 3 months ago

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Apr 14, 2025, 12:30 PM EDT - 3 months ago

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Apr 2, 2025, 8:30 AM EDT - 3 months ago

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Mar 26, 2025, 8:30 AM EDT - 4 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Mar 3, 2025, 8:30 AM EST - 4 months ago

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Feb 28, 2025, 8:30 AM EST - 4 months ago

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Feb 26, 2025, 8:30 AM EST - 5 months ago

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Feb 18, 2025, 8:30 AM EST - 5 months ago

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Feb 10, 2025, 9:00 AM EST - 5 months ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Feb 3, 2025, 8:30 AM EST - 5 months ago

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Jan 23, 2025, 11:00 AM EST - 6 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Dec 23, 2024, 10:00 AM EST - 7 months ago

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nov 26, 2024, 10:00 AM EST - 8 months ago

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nov 1, 2024, 2:00 PM EDT - 9 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Nov 1, 2024, 10:34 AM EDT - 9 months ago

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 1, 2024, 9:00 AM EDT - 9 months ago

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LOBO

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

Oct 28, 2024, 8:30 AM EDT - 9 months ago

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Oct 25, 2024, 9:00 AM EDT - 9 months ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CLDI

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Oct 22, 2024, 2:15 PM EDT - 9 months ago

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients

Oct 17, 2024, 8:30 AM EDT - 9 months ago

New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Oct 14, 2024, 8:30 AM EDT - 9 months ago

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

Sep 5, 2024, 9:00 AM EDT - 11 months ago

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 26, 2024, 9:55 AM EDT - 1 year ago

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LOBO

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

Jul 18, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

Nexalin Technology Announces Closing of $5.2 Million Public Offering

Jul 1, 2024, 2:45 PM EDT - 1 year ago

Nexalin Technology Announces Closing of $5.2 Million Public Offering

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

Jun 27, 2024, 9:15 PM EDT - 1 year ago

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and Dementia

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and Dementia

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jun 14, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VNRX

Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

Jun 13, 2024, 3:00 PM EDT - 1 year ago

Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

Jun 3, 2024, 8:30 AM EDT - 1 year ago

FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

May 22, 2024, 8:30 AM EDT - 1 year ago

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

Nexalin Technology CEO Provides Letter to Shareholders

Apr 10, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology CEO Provides Letter to Shareholders

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

Apr 4, 2024, 1:00 PM EDT - 1 year ago

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

Apr 2, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Mar 28, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology

Mar 14, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

Mar 13, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

Mar 6, 2024, 8:30 AM EST - 1 year ago

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Feb 8, 2024, 8:30 AM EST - 1 year ago

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

Jan 23, 2024, 8:30 AM EST - 1 year ago

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

Nexalin Technology Unveils Next-Generation HALO™ Clarity

Jan 11, 2024, 8:30 AM EST - 1 year ago

Nexalin Technology Unveils Next-Generation HALO™ Clarity

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

Dec 18, 2023, 8:30 AM EST - 1 year ago

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

NewYorkBull
NewYorkBull Jul. 16 at 7:09 PM
$NXL guys I'm a proud owner. This will change lives if you hold through next year. I promise you we'll have trial data and a lot more.
0 · Reply
Painman
Painman Jul. 9 at 6:45 PM
$NXL 💩💩💩
0 · Reply
Painman
Painman Jun. 26 at 5:16 PM
$NXL ..Total POS scam being run by Len Osser
0 · Reply
Chrissytina
Chrissytina Jun. 25 at 1:14 PM
$NXL Anybody else noticed that since they took all these commercials off CNBC that most of them have crashed 🤣 crooks!!! Not complaining, I flipped 4 different ones 2/3 times! I want the commercials/volume to come back!!! 🙏🏻
1 · Reply
Painman
Painman Jun. 17 at 2:30 PM
$NXL ..💩💩🤪
0 · Reply
Msnlrainey
Msnlrainey May. 31 at 11:03 PM
$NXL back on tv again with red chip
0 · Reply
Painman
Painman May. 20 at 7:15 PM
$NXL Total garbage..🐕💩POS.. You can’t do deep brain stimulation or treat Alzheimer’s with skin electrodes! Check it out just another Lenny scam.
0 · Reply
TheLearnerEarner
TheLearnerEarner May. 15 at 3:08 PM
$NXL ✅ Healthcare - Micro Cap - Oversold F-Score: 3/9 🏦 Analysts: 1x buy rating 👨‍🔬 Potential: Revenue is forecast to grow per year 💎 Highest Analysts Price Target: $5.00 (309% above Price) 🌟 Range (12m) $0.53 - $4.49 💰 NEWSDESK (last recent article) 📰 https://www.stocktitan.net/news/NXL/nexalin-technology-reconstitutes-scientific-advisory-board-with-ja58t2vt6l1v.html
0 · Reply
Mohammed_kas
Mohammed_kas May. 13 at 2:09 PM
$NXL The news is good and this is red😔
0 · Reply
Mohammed_kas
Mohammed_kas May. 13 at 1:12 PM
$NXL Nexalen Technology reconstitutes its scientific advisory board with leading experts to advance its Alzheimer's program amid encouraging data.
0 · Reply
Mohammed_kas
Mohammed_kas May. 12 at 6:22 PM
$NXL Added✅
0 · Reply
NewYorkBull
NewYorkBull May. 12 at 2:30 PM
$NXL piece of shit stock, selling when market is green. Is this ever going green or is it done into the abyss?
2 · Reply
Mohammed_kas
Mohammed_kas May. 8 at 4:50 PM
$NXL More added ✅
0 · Reply
Painman
Painman May. 6 at 11:46 PM
$NXL ..Lenny The Scum needed extra cash to keep paying his salary and his wife is on the payroll too! Total Fukkin scam.. Good luck Bag Holders Because Ur screwed
0 · Reply
Mohammed_kas
Mohammed_kas May. 6 at 6:48 PM
$NXL Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering👍🏻👍🏻
0 · Reply
Stock_trading_paint
Stock_trading_paint May. 6 at 2:24 PM
$NXL they need some operating capital to really fully launch their product. stings in the short term. just gota chill and wait til summer with this one .
0 · Reply
Rblanche
Rblanche May. 6 at 1:36 PM
$NXL
0 · Reply
Mohammed_kas
Mohammed_kas May. 6 at 1:06 PM
$NXL move ✅💚
0 · Reply
PenkeTrading
PenkeTrading May. 6 at 8:40 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Nexalin Technology Inc.. Is that bullish or bearish? $NXL #RsiOversold #NASDAQ
0 · Reply
Mohammed_kas
Mohammed_kas May. 5 at 4:30 PM
$NXL ✅💚💚
0 · Reply
Painman
Painman May. 5 at 1:39 PM
$NXL .. you poor bastards.. company is a scam led by a notorious, scumbag, and all products come from China!
0 · Reply
Chrissytina
Chrissytina May. 5 at 1:07 PM
$NXL Guess this falls under a dollar today 🤦🏼‍♀️
1 · Reply